Peanut Immunotherapy

Phase 2Small molecule

UUniversity of North Carolina, Chapel Hill

Peanut Immunotherapy is one of 22 small molecule programs targeting Allergy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AllergyEnrolling by invitation

AllergyPhase 2

Enrolling by invitation

Competition

Competitive Landscape

30 competitors in Allergy

#DrugCompanyPhaseTrials

Biaxin

AbbVie

Approved

1 2

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

6 3

Flagyl

DDePuy Orthopaedics

Approved

1 4

Potassium Citrate

MMission Pharmacal

Approved

1 5

Levaquin

WWim Janssens

Approved

1 6

Achromycin V

WWyeth-Lederle Vaccines

Approved

1 7

Allegra

CChattem

Approved

1 8

Claritin

PPerrigo Company

Approved

1 9

Nexium

DDexcel Pharma Technologies Ltd.

Approved

1 10

Lastacaft

AbbVie

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Recruiting

Peanut Allergy

NCT07015996

Clinical

Trials by Indication[1]

Allergy4 trials

Food Oral Immunotherapy for Peanut Allergy

Enrolling by invitation·MMassachusetts General Hospital·Phase 2·NCT04222491·500 enrolled

Peanut Oral Immunotherapy in Children With Peanut Allergy (Peanut Flour)

Completed·—·Phase 1·NCT02203799·15 enrolled

Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy

Completed·UUniversity of North Carolina, Chapel Hill·Phase 1/2·NCT00932282·13 enrolled

Show 1 more trial

Pilot Study on Immunotherapy for the Treatment of Persistant Peanut Allergy

Terminated·UUniversity Hospital, Geneva·Phase 1/2·NCT04974970·12 enrolled

Immunotherapy1 trial

Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT00932828·37 enrolled

Peanut Allergy1 trial

Efficacy of Tezepelumab in Peanut Oral Immunotherapy: a Double-Blind, Randomized, Placebo-Controlled Trial

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT07015996·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Peanut Immunotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Peanut Immunotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Peanut Immunotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of North Carolina, Chapel Hill company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of North Carolina, Chapel Hill

Peanut Immunotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Allergy4 trials

Immunotherapy1 trial

Peanut Allergy1 trial

References

Drug Info

Quick Facts

Related News